This study provides, compelling evidence that suggests a targeting strategy involving the functional interaction between miR-424(322) and the PD-L1/PD-1 immune checkpoint signalling to treat chemoresistant ovarian cancer. This evidence concerns the gene CD274 and ovarian cancer.